Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008

Ovarian Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 50 articles: HTML format

Single Articles

May 2008
1. AEBI S , Castiglione M
   Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
   Ann Oncol. 2008;19 Suppl 2:ii14-6.
   PubMed     Related articles   
   
   
   April 2008
2. ZHONG Q , Wen YJ, Yang HS, Luo H, et al
   Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
3. RAPP K , Klenk J, Ulmer H, Concin H, et al
   Weight change and cancer risk in a cohort of more than 65,000 adults in Austria.
   Ann Oncol. 2008;19:641-8.
   PubMed     Related articles    Abstract available
   
   
   
4. FULCINITI F , Losito S, Botti G, Di Mattia D, et al
   Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years.
   Ann Oncol. 2008;19:682-7.
   PubMed     Related articles    Abstract available
   
   
   February 2008
5. BARRETT SV , Paul J, Hay A, Vasey PA, et al
   Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   January 2008
6. THASNI KA , Rakesh S, Rojini G, Ratheeshkumar T, et al
   Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   December 2007
7. NAWA A , Suzuki K, Kato S, Fujiwara S, et al
   Carbon beam therapy in recurrent ovarian cancer.
   Ann Oncol. 2007;.
   PubMed     Related articles   
   
   
   
8. PRAT A , Parera M, Peralta S, Perez-Benavente MA, et al
   Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.
   Ann Oncol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   November 2007
9. SWART AM , Burdett S, Ledermann J, Mook P, et al
   Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
   Ann Oncol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
10. MARCHINI S , Marabese M, Marrazzo E, Mariani P, et al
    {Delta}Np63 expression is associated with poor survival in ovarian cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
11. OYEN WJ , Bodei L, Giammarile F, Maecke HR, et al
    Targeted therapy in nuclear medicine--current status and future prospects.
    Ann Oncol. 2007;18:1782-92.
    PubMed     Related articles    Abstract available
    
    
    October 2007
12. BRESSER PJ , Van Gool AR, Seynaeve C, Duivenvoorden HJ, et al
    Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?
    Ann Oncol. 2007;18:1641-5.
    PubMed     Related articles    Abstract available
    
    
    September 2007
13. LIN A , Yan WH, Xu HH, Gan MF, et al
    HLA-G expression in human ovarian carcinoma counteracts NK cell function.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
14. JAHAN I , Fujimoto J, Alam SM, Sato E, et al
    Role of protease activated receptor-2 in tumor advancement of ovarian cancers.
    Ann Oncol. 2007;18:1506-12.
    PubMed     Related articles    Abstract available
    
    
    August 2007
15. PAUTIER P , Ribrag V, Duvillard P, Rey A, et al
    Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
16. PISANO C , Vesci L, Fodera R, Ferrara F, et al
    Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    July 2007
17. LARKIN JM , Kaye SB
    Potential clinical applications of epothilones: a review of phase II studies.
    Ann Oncol. 2007;18 Suppl 5:v28-34.
    PubMed     Related articles    Abstract available
    
    
    
18. LORUSSO D , Di Stefano A, Carone V, Fagotti A, et al
    Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
    Ann Oncol. 2007;18:1159-64.
    PubMed     Related articles    Abstract available
    
    
    June 2007
19. RUSSO A , Calo V, Augello C, Bruno L, et al
    4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).
    Ann Oncol. 2007;18 Suppl 6:vi99-102.
    PubMed     Related articles    Abstract available
    
    
    
20. VESCHI S , Aceto G, Scioletti AP, Gatta V, et al
    High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.
    Ann Oncol. 2007;18 Suppl 6:vi86-92.
    PubMed     Related articles    Abstract available
    
    
    May 2007
21. BIJELIC L , Jonson A, Sugarbaker P
    Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
22. WANG Y , Kristensen G, Borresen-Dale AL, Helland A, et al
    TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.
    Ann Oncol. 2007;18:964-6.
    PubMed     Related articles   
    
    
    
23. RIEDINGER JM , Bonnetain F, Basuyau JP, Eche N, et al
    Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.
    Ann Oncol. 2007;18:881-5.
    PubMed     Related articles    Abstract available
    
    
    
24. AYANTUNDE AA , Parsons SL
    Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
    Ann Oncol. 2007;18:945-9.
    PubMed     Related articles    Abstract available
    
    
    
25. 
    Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
    Ann Oncol. 2007;18 Suppl 2:ii12-ii14.
    PubMed     Related articles       Free Full Text
    
    
    April 2007
26. FERRANDINA G , Ludovisi M, De Vincenzo R, Salutari V, et al
    Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    February 2007
27. ANDREOPOULOU E , Gaiotti D, Kim E, Downey A, et al
    Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    January 2007
28. ZOLA P , Ferrero A
    Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients?
    Ann Oncol. 2007;.
    PubMed     Related articles   
    
    
    
29. PSYRRI A , Kountourakis P, Yu Z, Papadimitriou C, et al
    Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    December 2006
30. PIJNENBORG J , Dam-de Veen G, Kisters N, Delvoux B, et al
    RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    November 2006
31. FERRERO JM , Weber B, Geay JF, Lepille D, et al
    Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
32. HILPERT F , du Bois A, Greimel ER, Hedderich J, et al
    Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
33. TREDAN O , Geay JF, Touzet S, Delva R, et al
    Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    October 2006
34. PFISTERER J , du Bois A, Sehouli J, Loibl S, et al
    The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
    Ann Oncol. 2006;17:1568-1577.
    PubMed     Related articles    Abstract available
    
    
    September 2006
35. BAMIAS A , Yu Z, Weinberger PM, Markakis S, et al
    Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with {beta}-catenin levels and outcome in patients with epithelial ovarian cancer.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
36. EISENHAUER EA
    New targets and non-cytotoxics in ovarian cancer.
    Ann Oncol. 2006;17 Suppl 10:x247-x250.
    PubMed     Related articles   
    
    
    
37. VERMORKEN JB
    Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last.
    Ann Oncol. 2006;17 Suppl 10:x241-x246.
    PubMed     Related articles   
    
    
    
38. DU BOIS A , Harter P
    The role of surgery in advanced and recurrent ovarian cancer.
    Ann Oncol. 2006;17 Suppl 10:x235-x240.
    PubMed     Related articles   
    
    
    June 2006
39. RIEDINGER JM , Wafflart J, Ricolleau G, Eche N, et al
    CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
40. PIGNATA S , Pisano C, Di Maio M, Iodice F, et al
    Medical treatment of resistant or recurrent epithelial ovarian cancer.
    Ann Oncol. 2006;17 Suppl 7:vii49-vii50.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
41. LEGGE F , Ferrandina G, Scambia G
    From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer.
    Ann Oncol. 2006;17 Suppl 7:vii46-vii48.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
42. CAPALBO C , Ricevuto E, Vestri A, Ristori E, et al
    BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Ann Oncol. 2006;17 Suppl 7:vii34-vii40.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    May 2006
43. SCARFONE G , Bolis G
    Multimodal approach to ovarian cancer.
    Ann Oncol. 2006;17 Suppl 5:v199-v200.
    PubMed     Related articles       Free Full Text
    
    
    
44. GALLIGIONI E , Arcuri C, Sorio R, Griso C, et al
    Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
    Ann Oncol. 2006;17 Suppl 5:v195-v198.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
45. LORUSSO D , Di Stefano A, Fanfani F, Scambia G, et al
    Role of gemcitabine in ovarian cancer treatment.
    Ann Oncol. 2006;17 Suppl 5:v188-v194.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
46. OZOLS RF
    Challenges for chemotherapy in ovarian cancer.
    Ann Oncol. 2006;17 Suppl 5:v181-v187.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    April 2006
47. SEHOULI J , Oskay-Ozcelik G, Kuhne J, Stengel D, et al
    Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
    Ann Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    February 2006
48. HOTTE SJ , Oza A, Winquist EW, Moore M, et al
    Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Ann Oncol. 2006;17:334-40.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    November 2005
49. DU BOIS A , Burges A, Meier W, Pfisterer J, et al
    Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
    Ann Oncol 2005;.
    PubMed     Related articles    Abstract available
    
    
    October 2005
50. DELORD JP , Allal C, Canal M, Mery E, et al
    Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.
    Ann Oncol 2005;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: